A Treatment Specifically Designed for IgA Nephropathy, an AAKP HealthLine Innovator webinar

Поделиться
HTML-код
  • Опубликовано: 24 авг 2024
  • A Treatment Specifically Designed for IgA Nephropathy, an AAKP HealthLine Innovator webinar sponsored by Calliditas Therapeutics
    Join this webinar to learn about a treatment specifically designed for IgA Nephropathy. During this webinar, you will learn more about IgA Nephropathy, discover a treatment that was specifically designed for this disease, and review clinical trial results.
    Speaker: Jonathan Barratt, PhD, FRCP; Renal Research Group, Department of Life Sciences, University of Leicester
    Moderator: Erin Kahle, MPA, CNP; AAKP Director of Patient Insights, Data Analytics, and Advocacy
    The content of this program, as presented, and financial support of this webinar was provided by Calliditas Therapeutics.
    As the oldest and largest patient-led kidney patient organization in the U.S., AAKP is proud to host this Innovator webinar as a service to the expanding national and global communities of patient consumers and their families, medical practitioners, researchers, and policymakers following innovation and advancements in kidney care and treatment.
    AAKP is an aggressive supporter of innovation to change status quo care.
    While this activity is an approved educational webinar, AAKP does not endorse this webinar nor endorse or promote any specific commercial entities or products.
    As the oldest and largest, independent kidney patient organization in the U.S. - AAKP is dedicated to improving the lives and long-term outcomes of kidney patients through education, advocacy, patient engagement, and the fostering of patient communities. AAKP fights for early disease detection and the appropriate diagnosis of rare/genetic conditions; increased kidney transplantation and pre-emptive transplantation; full patient choice of either in-center or home dialysis; protection of the patient/physician relationship; promotion of research and innovation including artificial implantable and wearable kidneys; and the elimination of barriers for patient access to available treatment options. Learn more at www.aakp.org.

Комментарии • 2

  • @MostaphaHabibAllah
    @MostaphaHabibAllah 6 месяцев назад

    Cost ?

  • @Max-bs9fs
    @Max-bs9fs Год назад

    My 4 year's son recently got diagonised with igA nephropathy😢